Update : Jun. 24, 2011
[Tokyo Stock Exchange, Inc.]
TOKYO AIM Inc., (“TOKYO AIM”) today announced that it has accepted the initial listing of Mebiopharm Co., Ltd. (“Mebiopharm”), a Japanese biotechnology firm, specializing in new drug development for cancer treatment. The expected listing date is July 15, 2011.
Further details on TOKYO AIM can be found at:
Tokyo Stock Exchange Group, Inc.